

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Shares or other securities of the Company.



Shunten International (Holdings) Limited

順騰國際(控股)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 932)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE ON LAUNCHING OF PROPOSED NEW PRODUCT LINE

This announcement is made on a voluntary basis by Shunten International (Holdings) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide its shareholders and potential investors with update on the business development of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that Royal Medic (Holdings) Limited, a wholly-owned subsidiary of the Company, has entered into a license agreement (the “**License Agreement**”) with The Walt Disney Company (Hong Kong) Limited (“**Disney HK**”), pursuant to which the Company is licensed by Disney HK on a non-exclusive basis since June 2021 to the use certain popular and renowned titles and characters of Disney, including Cars, Cars 2, Cars 3, Disney Princess, Dumbo, Finding Dory, Frozen, Mickey Mouse Family, Minnie, Pixar Collection, Disney Standard Characters and Toy Story 4, in the production and distribution of healthcare products within the territory of Hong Kong and Macau through physical distribution and retail channels as well as online store as approved by Disney HK. Under the License Agreement, such licensing arrangement shall last until June 2022. The healthcare

products to be launched with the licensed titles and characters applied will be subject to the final review and approval by Disney HK pursuant to its internal guidelines from time to time.

The Group plans to launch a new series of healthcare products targeted to children with the abovementioned license. Such products mainly include health supplement for children consumption. Since the entering into of the License Agreement, the Group has been planning, formulating and designing suitable products to be marketed by using the licensed titles and characters, and as at the date of this announcement, the review and approval by Disney HK of the proposed products of the Company has come to an advanced stage, and the Company targets to launch the new product line by the end of 2021. The Company will monitor the market performance of such new line of products when it is rolled out, and aims to develop long term cooperation in the licensing arrangement with Disney HK in future, and is prepared to liaise with Disney HK for the extension or renewal of the licensing arrangement in advance.

The License Agreement is entered into the ordinary course of business of the Group and the terms thereof are negotiated between the parties on an arm's length basis, and are fair and reasonable to the Company. The Board believes that the launching of the new product line will contribute to the development of the Group's health and beauty supplements and products business, and will create new business opportunities for the Group, which are in the interest of the Company and of its shareholders as a whole.

By order of the Board
Shunten International (Holdings) Limited
Wang Xihua
Executive Director

Hong Kong, 12 October 2021

As at the date of this announcement, the executive Directors are Mr. WANG Xihua and Mr. LAI Wei Lam, William; and the independent non-executive Directors are Mr. LEUNG Winson Kwan Yau, Mr. TAM Kin Yip and Mr. LEUNG Man Loon.